Elevation Oncology (NASDAQ:ELEV) Receives “Buy” Rating from HC Wainwright
Elevation Oncology (NASDAQ:ELEV – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $6.00 price objective on the stock. ELEV has been the topic of several other reports. William Blair reaffirmed an “outperform” rating and issued a $5.00 […]
Elevation Oncology (NASDAQ:ELEV – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $6.00 price objective on the stock. ELEV has been the topic of several other reports. William Blair reaffirmed an “outperform” rating and issued a $5.00 […]
